How Prior Auth Delays Affect Patient Outcomes: What the Research Shows

Prior authorization was supposed to be a utilization management tool. What it became is something else entirely.

Physicians now spend an average of 13 hours per week on PA tasks — nearly two full workdays consumed by forms, phone calls, and waiting. That number comes straight from the AMA's 2024 Prior Authorization Physician Survey. And while 13 hours of administrative waste is a real problem, it's not the most serious one. The most serious problem is what happens to patients while the paperwork piles up.

The Numbers Are Hard to Look At

The same AMA survey found that 93% of physicians reported PA caused care delays. Not occasionally. Consistently. As a structural feature of how the system operates.

More than 1 in 4 physicians reported a PA delay leading to a serious adverse event for a patient. That's not a data artifact — it maps directly to what clinicians see every day: a patient with active disease waiting 3, 5, sometimes 10 or more business days for a treatment decision.

Research published in Health Affairs documented the downstream consequences with more precision. Patients facing PA delays were significantly more likely to experience disease progression, require emergency care, or need more intensive interventions than they would have needed with timely treatment. The math works in the wrong direction: a cheaper drug held up by a 14-day approval process costs the system far more when the patient eventually lands in the emergency department.

Specialty by Specialty: Where Delays Hurt Most

PA delays don't hit every specialty equally. Some patients can tolerate a wait better than others. Some can't.

Oncology is the hardest case. For patients with cancer, delays in systemic therapy or targeted biologics aren't inconveniences — they're clinical events. Research in JAMA Oncology has established that treatment delays beyond four weeks in certain cancers correlate with measurably worse overall survival. PA timelines that routinely run two to three weeks — with a denial and appeal adding another two weeks — can land a patient squarely in that danger zone. And yet oncology biologics face some of the most intensive PA scrutiny of any drug category.

Rheumatology tells a different story, but not a better one. Inflammatory diseases like rheumatoid arthritis and psoriatic arthritis cause permanent joint damage during periods of uncontrolled disease activity. A patient who waits six weeks for a biologic approval while their CRP climbs and their joints degrade has sustained real, irreversible harm — even if the drug eventually gets approved. Studies from the American College of Rheumatology have been direct on this point: PA processes that extend active inflammatory disease periods contribute to worsening functional outcomes.

Neurology faces its own specific problem. For patients with multiple sclerosis, the window for disease-modifying therapy to be effective is tied to limiting cumulative lesion burden. Delays mean more lesions. More lesions mean more disability. This isn't a theoretical concern — neurologists document it in their practices every week.

Treatment Abandonment: The Outcome Nobody Reports

Here's what tends not to make it into outcome studies: the patients who just stop trying.

When approval takes too long, some patients don't wait. They give up on the medication, stop following up, or find workarounds that don't involve the drug their physician actually wanted them on. The AMA survey found that 78% of physicians reported PA causing patients to abandon recommended treatment. Nearly 1 in 3 patients who encounter a PA barrier abandon the treatment entirely.

That abandoned treatment doesn't get recorded as a PA outcome. It gets recorded as nothing — the patient just disappears from the treatment pathway. Their disease continues. Their health deteriorates. The data never connects it back to the three weeks they spent waiting for an approval that never came, or came too late to matter.

The Hospitalization Cost Nobody Wants to Calculate

The systemic cost of PA delays extends well beyond individual clinical encounters.

When biologics for inflammatory bowel disease are delayed, patients with Crohn's disease or ulcerative colitis are at higher risk of disease flares requiring hospitalization. The cost of a single hospitalization for a Crohn's flare — typically $15,000 to $30,000 — dwarfs the cost of the biologic that might have prevented it. This isn't speculation. Published gastroenterology research has documented this dynamic directly, finding that PA-related delays in biologic initiation were associated with significantly higher rates of subsequent hospitalization.

The insurer that denied the claim to avoid the drug cost often ends up paying far more for the hospitalization that followed. The patient absorbs the health consequences of both.

What Policymakers Are — Slowly — Doing About It

There's been real movement at the regulatory level, even if implementation has lagged.

The CMS Prior Authorization Rule that took effect in 2024 established binding turnaround requirements for Medicare Advantage and Medicaid: 72 hours for urgent requests, 7 calendar days for standard requests. Before that rule, wait times were effectively uncapped. Plans could — and did — take weeks.

Several states have enacted PA reform laws that mirror or exceed CMS requirements. These laws vary by state but generally include time limits, gold carding provisions for physicians with strong approval track records, and transparency requirements for denial criteria. Progress is real, if uneven.

Still, being compliant with the law and being fast are different things. A 7-day turnaround is much better than a 3-week turnaround. It's still 7 days of a patient waiting with active disease.

What Providers Can Do Now

Regulatory reform helps at the system level. At the practice level, the most effective lever is documentation quality on the first submission.

Most PA denials aren't denials of the clinical case — they're denials of incomplete documentation. Research across the prior authorization literature consistently finds that the majority of overturned denials were overturned because the clinical information was always there; it just wasn't captured in the initial request.

Submitting complete, payer-specific documentation on the first attempt is the single most effective way to shorten the approval timeline — and by extension, reduce the clinical risk patients face during the delay period. That means knowing the exact criteria each payer uses for each biologic, mapping patient clinical data to those criteria precisely, and not leaving gaps that give automated review systems an easy reason to deny.

Faster documentation means faster submission. Faster submission means less time between prescription and treatment. For patients with aggressive inflammatory disease or cancer, that time is not administrative. It's clinical.

Sources:
American Medical Association. (2024). 2024 AMA Prior Authorization Physician Survey. ama-assn.org
Dusetzina, S.B., et al. (2023). Prior Authorization and Patient Outcomes. Health Affairs. healthaffairs.org
Marron, J.M., et al. (2022). Prior Authorization for Cancer Therapies. JAMA Oncology. jamanetwork.com
American College of Rheumatology. (2023). Position Statement: Prior Authorization. rheumatology.org
Yarur, A., et al. (2022). Prior Authorization Delays and IBD Hospitalization Rates. Gastroenterology. gastrojournal.org